International Business Machines Corporation

Hypnion, Inc.

Engelhard Corporation

Air Products and Chemicals, Inc.

Colucid Pharmaceuticals, Inc.

Other

Basf Catalysts LLC

James F White

David G Hangauer

Dale M Edgar

Michael E Solomon

Kazumi Shiosaki

James K Howard

Paul A Totta

Kenneth Parker Rodbell

Daniel Coughlin

Evan G Colgan

Kris V Srikrishnan

Thomas Hsiao-Ling Hsiung

Maris A Sturans

Wei-Kan Chu

Robert R Wilbarg

Jer-Ming Yang

George J Giuffre

Jeffrey James Ramler

William D Rosenberg

Nadia M J Rupniak

Richard Anthony Conti

Gamini Ananda Vedage

Patrick William Dehaven

Michael J Sullivan

Timothy Martin Reith

John James Gniewek

Bharat Lajjaram Bhatt

John J Lewnard

Kenneth L DeVries

Laura B Rothman

Harry Jefferson Leighton

Robert A Treskot

J David Leander

Emmanuel J M Mignot

Richard J Jenkins

J Daniel Mis

Shoucheng Du

Frank E Turene

Alison Pilgrim

Geoffrey White

Barbara Slawski

Thomas H Hsuing

Michael Solomon

The present invention relates to discloses a pharmaceutical composition of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharmaceutically acceptable carrier.

Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide

A method for making a high activity ortho-para hydrogen conversion catalyst is set forth wherein a solution of ruthenium cation is mixed with a solution of a poorly coordinating anion such as aluminate to form a precipitate and the precipitate-containing solution is adjusted to a pH of 7 before recovering the catalyst. A product of this process and a method of using such product is disclosed.

Catalyst for conversion and equilibration of para and ortho hydrogen

The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.

Benzisoxazole piperidine compounds and methods of use thereof

Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

Compounds that inhibit cholinesterase

The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.

Benzisoxazole piperazine compounds and methods of use thereof

The invention relates to novel compounds and methods of using them for modulating sleep.

Olanzapine analogs and methods of use thereof

Loxapine analogs and methods of use thereof

One aspect of the invention relates to a catalyst composite containing an extruded catalyst support containing an extruded activated carbonaceous material having specifically a defined pore structure. For example, the extruded activated carbonaceous material may have pores wherein at least about 40% of total Hg porosity occurs in pores having a diameter of about 200 &#x212b; and larger. Alternatively the extruded activated carbonaceous material may have a first set of pores having a pore diameter of at least about 40 &#x212b; and at most about 100 &#x212b; with a porosity of at least about 0.15 cc/g, and a second set of pores having a pore diameter of at least about 5,000 &#x212b; and at most about 20,000 &#x212b; with a porosity of at least about 0.3 cc/g.

Catalyst for purification of aromatic acids

Quetiapine analogs and methods of use thereof

The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

Methods of treating sleep disorders

The invention relates to novel doxepin analog compounds and methods of modulating sleep by administering such compounds, or a pharmaceutically effective salt thereof.

Doxepin analogs and methods of use thereof

The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.

Treatment of CNS disorders using CNS target modulators

Growing community of inventors

Newburgh, NY, United States of America

James F White